Industries / Frontier science / Cell and gene therapy
Paying and reaching patients
This work sets prices for treatments given once that cost hundreds of thousands to millions of dollars, finds ways for health systems to pay for them, and gets patients to the few centres that can give them.
7
Milestones achieved, from 2016 to 2025.
2
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
2016
A refund if it fails
Strimvelis, a gene therapy for the inherited immune disease ADA-SCID developed at the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET) in Milan, was authorised in the EU on 26 May 2016. Italy's medicines agency, AIFA, set the price at EUR 594,000 after GSK opened at "nearly double", on terms under which GSK repays the money if the treatment fails; AIFA's director, Luca Pani, said Italy had collected more than EUR 250 million in such refunds across drugs. It is given only at San Raffaele Hospital, so families travel to Milan.
Lessona price agreed for about a dozen European births a year did not keep the medicine commercial; it later passed to Orchard Therapeutics, and on 17 July 2023 the European Commission moved its licence to the charity Fondazione Telethon, which now supplies it.
Credit
GSK; AIFA; SR-TIGET
2019
Two million dollars, over time
When the FDA approved Zolgensma on 24 May 2019, its maker AveXis set the US list price at USD 2.125 million. It offered payers instalments of USD 425,000 a year for up to 5 years and outcomes-based agreements, in which payment depends on results, lasting up to 5 years, and said the price was half its estimate of USD 4.1 million for 10 years of existing SMA treatment.
Credit
AveXis, a Novartis company
2021
A maker leaves Europe
On 10 August 2021 bluebird bio said it would wind down its European business because the prices payers offered made it "untenable". It had set an initial price of USD 1.8 million for Zynteglo, its one-time gene therapy for the blood disorder beta-thalassaemia, had offered to spread payments over five years tied to results, and had already pulled Zynteglo from Germany after failing to agree a price there.
Lessonan EU-wide licence does not bring a therapy to patients; each country's payer still has to agree a price.
Credit
bluebird bio
2021
A hospital's own CAR-T
In February 2021 Spain's medicines agency, AEMPS, authorised ARI-0001 (varnimcabtagene autoleucel), a CAR-T therapy developed and made at Hospital Clínic de Barcelona, under the hospital exemption, for adults over 25 with acute lymphoblastic leukaemia that has come back or resisted treatment. In August 2024 AEMPS authorised a second in-house CAR-T from the same hospital, ARI-0002h, for multiple myeloma, and in 2026 the hospital's head of immunology said it had made doses for nearly 700 patients.
Credit
Hospital Clínic de Barcelona (Manuel Juan, Álvaro Urbano-Ispizua, Gonzalo Calvo); AEMPS
2023
A tenth of the price
In October 2023 India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved ImmunoACT's NexCAR19 (actalycabtagene autoleucel), the first CAR-T approved in India, for B-cell lymphomas and leukaemia that have come back or resisted treatment. By GlobalData's account the approval rested on an Indian phase I/II trial in 60 people with a 70% overall response rate, and ImmunoACT's chief executive gave a price of INR 30 to 40 lakh (INR 3 to 4 million, about USD 36,000 to 48,000), which GlobalData put at a tenth of the cost of CAR-T therapies approved elsewhere.
Credit
ImmunoACT
2025
Approved, then dropped
The FDA approved Pfizer's Beqvez, a one-time gene therapy for the bleeding disorder haemophilia B, on 25 April 2024, and it was also authorised in Canada and the EU, where it is called Durveqtix. In February 2025 Pfizer said it would stop developing and selling it, citing "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies to date".
Lessonwhere an existing treatment works, patients weigh a one-time therapy against unknowns about long-term safety, and demand can stay too low to keep an approved product on sale.
Credit
Pfizer
2025
One negotiator for many states
Under its Cell and Gene Therapy Access Model, the US Centers for Medicare & Medicaid Services (CMS) negotiated outcomes-based agreements, with discounts and rebates tied to results, with the makers of the two sickle-cell gene therapies on behalf of state Medicaid programmes, which joined between January 2025 and January 2026. CMS calls it the first time the federal government has negotiated such agreements for state Medicaid agencies. By CMS's own evaluation, 34 state and territory programmes joined, covering 84% of Medicaid beneficiaries with sickle cell disease.
Credit
CMS Innovation Center; Vertex Pharmaceuticals; Genetix Biotherapeutics
Watch for
The CMS model widens
On 27 October 2026 CMS said it would open the model to makers of cell and gene therapies for diseases other than sickle cell, with negotiations able to start right after FDA approval, citing its first evaluation.
Achieved whena therapy for another disease has CMS-negotiated terms and states have adopted them.
Claimed by
CMS Innovation Center, October 2026
CAR-T made in Colombia
A trial registered in February 2026 plans to make Hospital Clínic's ARI-0001 cells in Bogotá and give them to 12 adults with CD19-positive blood cancers that have come back or resisted treatment, to test safety and whether local production works, alongside a public-private plan for CAR-T care in Colombia. It was not yet recruiting when read, with an estimated start in September 2026.
Achieved whenpatients have been treated with cells made in Colombia and the safety and production results are published.
Claimed by
Gustavo Salguero, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud (IDCBIS), with Colombia's Instituto Nacional de Cancerología, February 2026
Open
01
A world map of centres
An open map of every centre authorised to give each approved CAR-T and gene therapy, country by country, with the share of each country's population within 1 and 2 hours' drive of one, refreshed each quarter.
The briefCredit · unclaimed02
A register of pay-for-results deals
A public table of every announced agreement, anywhere, that ties payment for a cell or gene therapy to how patients do: product, payer, country, outcome measured, time window, refund or rebate share where published, and the source.
The briefCredit · unclaimed
Open 01 · the brief
A world map of centres
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
An open map of every centre authorised to give each approved CAR-T and gene therapy, country by country, with the share of each country's population within 1 and 2 hours' drive of one, refreshed each quarter.
Why it is still open
The travel studies found cover single countries. A 2026 University of Maryland analysis of 169 US centres for three CAR-T products found 70% of the US population (229 million people) within 60 minutes' drive of a centre and 30% beyond it; a 2025 Blood Advances study, summarised by AABB, found that Medicare patients living farther from a centre were less likely to get CAR-T. A 2025 London School of Hygiene & Tropical Medicine model for England found that if cell therapies for solid cancers were limited to the 15 existing CAR-T centres, 44% of patients would be more than an hour away. No worldwide map turned up in searches.
Built with what exists
Makers' "find a treatment centre" pages and national lists of centres; OpenStreetMap with an open routing engine such as OSRM or openrouteservice; an open population grid such as WorldPop; a web-browsing AI agent to collect and re-check centre lists each quarter, with a person reviewing every change.
First step
Collect the US centre lists for Yescarta, Kymriah and Breyanzi and rerun the 60-minute analysis to check the method against the 70% figure.
Done looks like
Centres for every FDA- or EMA-approved CAR-T and gene therapy mapped in at least 30 countries, each with a source link; the US 60-minute figure within 5 percentage points of the Maryland study's 70%; and two quarterly refreshes completed on schedule.
Open 02 · the brief
A register of pay-for-results deals
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public table of every announced agreement, anywhere, that ties payment for a cell or gene therapy to how patients do: product, payer, country, outcome measured, time window, refund or rebate share where published, and the source.
Why it is still open
A 2026 scoping review by Patel and colleagues found 23 publicly reported US agreements from January 2017 to January 2026 and says details of their structure, outcomes and execution "remain limited"; it left out every other country. A 2023 study by Drummond and colleagues tabled outcome-based agreements for five cell and gene therapies in France, Germany, Italy and Spain, but it is a one-off snapshot, and it marks several outcome measures as unknown under confidentiality agreements. No shared, updated list covers both.
Built with what exists
Company and payer press releases; national payer documents, such as AIFA's in Italy and NHS England's; the CMS model documents; an AI model such as Claude to pull fields with a quoted source sentence; a person checking each row; a CSV file in a public GitHub repository.
First step
Rebuild the 23 US agreements from the review's cited sources into a draft CSV, then add the European agreements in the 2023 table and the public Strimvelis and Zolgensma terms.
Done looks like
All 23 US agreements in the 2026 review included, plus agreements from at least five other countries, every field linked to its source, and a second person's check of 30 random fields finds at least 95% correct.